Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

The Digital International Liver Congress - The Annual Meeting of the European Association for the Study of the Liver (EASL) – August 27-29, 2020

• Title: Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment
• Authors: Edward Gane, et al.
• Type: Oral Presentation
• Date and Time: August 28, 2020 at 13:30 CEST

European Society of Cardiology (ESC) Congress 2020 – August 29 - September 1, 2020

• Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects With Inherited Apolipoprotein C-3 Deficiency
• Authors: Christian Schwabe, et al.
• Presenter: Christie M. Ballantyne
• Type: Oral Presentation
• Date and Time: August 31, 2020 at 10:50 CEST

• Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia
• Authors: Gerald F. Watts, et al.
• Type: Oral Presentation
• Date and Time: August 31, 2020 at 11:00 CEST

A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.